Subtype
Osteosarcoma
CI-CAN-00001321Explore in graph →
99 active trials6 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001321Explore in graph →
Clinical trials
349 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (40)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06726512 | Quantitative Margin Assessment Using High-resolution Positron Emission Tomography - Computed Tomograhy(qMAP) | not yet recruiting | N/A | 30 | University Medical Center GroningenOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06714383 | Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma | recruiting | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Dec 3, 2024 |
| clinicaltrials |
| NCT06699576 | ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. | not yet recruiting | Phase 1 | 448 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Nov 21, 2024 | clinicaltrials |
| NCT06029218 | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy(P1V2) | recruiting | N/A | 106 | Centre Antoine LacassagneOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05830123 | ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas | recruiting | Phase 2 | 170 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06524778 | Single High-dose Brachytherapy for Giant Osteosarcoma Masses | not yet recruiting | Phase 2 | 16 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT04132895 | ICONIC: Improving Outcomes Through Collaboration in OsteosarComa(ICONIC) | recruiting | — | 300 | University College, LondonOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06324916 | Donor Site Morbidity After Free Vascularized Fibular Graft | recruiting | — | 20 | Assiut UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05535283 | Assessing Clinical Trial Experiences of Patients With Osteosarcoma | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial(PROMIS) | recruiting | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05328258 | Use of GnRHa During Chemotherapy for Fertility Protection(ProFertil) | recruiting | Phase 3 | 500 | Kenny Rodriguez-WallbergOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06041490 | Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | not yet recruiting | Phase 2 | 88 | Peking Union Medical College HospitalOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04758000 | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse(Metform-Bone) | recruiting | Phase 2 | 67 | Istituto Ortopedico RizzoliOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05590572 | A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | not yet recruiting | Phase 1 / Phase 2 | 148 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Oct 21, 2022 | clinicaltrials |
| NCT05515068 | Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas(COSS-Registry) | not yet recruiting | — | 1,000 | Klinikum StuttgartOTHER | 0 | Aug 25, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Dec 10, 2024source: clinicaltrials